High-throughput screening

To systematically identify potent inhibitors of Rac1 GTPases, we have built a customized, high-throughput platform that rapidly assesses inhibitory activity of tens of thousands of compounds.  Our platform integrates expert medicinal chemistry and in silico modeling with our cascade of biochemical and cell-based assays.

Selective targeting assays

Because there are different mechanisms of deregulation of Rac1, our ability to selectively address specific Rac isoforms, including genomic variants and wild type forms, is a critical capability of our drug discovery platform. Revere has developed target selectivity assays which allow us to identify selective Rac1 inhibitors and enable development of drugs for patient populations defined by Rac1 genomic variants.